Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer

被引：0
|
作者：
Isobe, K. [1 ]
Kobayashi, H. [1 ]
Isshiki, T. [1 ]
Sakamoto, S. [1 ]
Takai, Y. [1 ]
Tomida, T. [2 ]
Adachi-Akahane, S. [2 ]
Kishi, K. [1 ]
机构：
[1] Toho Univ, Sch Med, Dept Resp Med, Tokyo, Japan
[2] Toho Univ, Sch Med, Dept Physiol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P34.07
引用
收藏
页码：S417 / S418
页数：2
相关论文
共 50 条
  • [41] Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumour DNA
    Hsu, W. F.
    Ho, H-L.
    Chiang, C. L.
    Jiang, Y.
    Karwowska, S. M.
    Yerram, R.
    Sharma, K.
    Sharma, A.
    Scudder, S.
    Tsai, C-M.
    Palma, J.
    Chiu, C-H.
    Chou, T-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 643 - 643
  • [42] Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.
    Xu, Yiquan
    Wang, Haibo
    Zheng, Xinlong
    Lin, Gen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Negative-predictive value of SUVmax for Ascertaining the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer
    Anai, Moriyasu
    Inoue, Hiroki
    Saruwatari, Koichi
    Oda, Seitaro
    Shiraishi, Shinya
    Akaike, Kimitaka
    Imamura, Kosuke
    Jodai, Takayuki
    Sakata, Shinya
    Iyama, Shinji
    Tomita, Yusuke
    Ichiyasu, Hidenori
    Sakagami, Takuro
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1072 - 1078
  • [44] EGFR mutation analysis in circulating tumor cells and matched tumor of patients with non-small cell lung cancer
    Toh, Chee Keong
    Sng, Natasha
    Loh, Marie
    Wong, Alvin
    Yeo, Wee-Lee
    Chin, Tan Min
    Ng, Min-En
    Lim, Wan-Teck
    Soong, Richie
    Soo, Ross A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S928 - S928
  • [45] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
    Nobuyuki Yamamoto
    Takeshi Mera
    Angela Märten
    Maximilian J. Hochmair
    Advances in Therapy, 2020, 37 : 759 - 769
  • [46] A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
    Yasuda, Hiroyuki
    Ichihara, Eiki
    Sakakibara-Konishi, Jun
    Zenke, Yoshitaka
    Takeuchi, Shinji
    Morise, Masahiro
    Hotta, Katsuyuki
    Sato, Mineyoshi
    Matsumoto, Shingo
    Tanimoto, Azusa
    Matsuzawa, Reiko
    Kiura, Katuyuki
    Takashima, Yuta
    Yano, Seiji
    Koyama, Junji
    Fukushima, Takahiro
    Hamamoto, Junko
    Terai, Hideki
    Ikemura, Shinnosuke
    Takemura, Ryo
    Goto, Koichi
    Soejima, Kenzo
    LUNG CANCER, 2021, 162 : 140 - 146
  • [47] Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients
    Xia, Shu
    Ye, Junyi
    Chen, Yu
    Lizaso, Analyn
    Huang, Le
    Ski, Lei
    Su, Jing
    Han-Zhang, Han
    Chuai, Shannon
    Li, Lingling
    Chen, Yuan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 1016 - 1028
  • [48] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
    Yamamoto, Nobuyuki
    Mera, Takeshi
    Maerten, Angela
    Hochmair, Maximilian J.
    ADVANCES IN THERAPY, 2020, 37 (02) : 759 - 769
  • [49] Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
    Green, John A.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3837 - S3839
  • [50] Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial
    de Marinis, Filippo
    Vergnenegre, Alain
    Passaro, Antonio
    Dubos-Arvis, Catherine
    Carcereny, Enric
    Drozdowskyj, Ana
    Zeaiter, Ali
    Perez-Moreno, Pablo
    Rosell, Rafael
    FUTURE ONCOLOGY, 2015, 11 (03) : 421 - 429
12345